Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 157

Results For "FY"

2443 News Found

Dr. Jitendra Singh launches multi-disciplinary post-doctoral courses in Bio-Sciences
News | February 06, 2024

Dr. Jitendra Singh launches multi-disciplinary post-doctoral courses in Bio-Sciences

1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector


Mandaviya inaugurates new headquarters of the National Dental Commission
News | February 06, 2024

Mandaviya inaugurates new headquarters of the National Dental Commission

Additionally, an MoU was signed between the Dental Council of India and Quality Council of India for the assessment and rating of undergraduate dental colleges


Industry’s reaction to Union Budget 2024-25
Policy | February 02, 2024

Industry’s reaction to Union Budget 2024-25

Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry


Zydus receives USFDA’s final approval for Gabapentin Tablets, 300 mg and 600 mg
Drug Approval | January 26, 2024

Zydus receives USFDA’s final approval for Gabapentin Tablets, 300 mg and 600 mg

Gabapentin is indicated for the management of Postherpetic Neuraligia


ImmunoBrain Checkpoint appoints Dr. Sanjay Keswani as CEO
People | January 24, 2024

ImmunoBrain Checkpoint appoints Dr. Sanjay Keswani as CEO

He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom


Novo Holdings expands portfolio in cancer diagnostics
News | January 22, 2024

Novo Holdings expands portfolio in cancer diagnostics

Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer


Zydus receives USFDA’s approvals for Pimavanserin Capsules, 34 mg and Pimavanserin Tablets,10 mg
Drug Approval | January 18, 2024

Zydus receives USFDA’s approvals for Pimavanserin Capsules, 34 mg and Pimavanserin Tablets,10 mg

Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis


NATCO invests US$ 2 million in Cellogen Therapeutics
News | January 18, 2024

NATCO invests US$ 2 million in Cellogen Therapeutics

Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy


Agilent announces new ProteoAnalyzer system
News | January 17, 2024

Agilent announces new ProteoAnalyzer system

Automated parallel capillary electrophoresis system simplifies protein analysis